Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

Dolutegravir is an HIV ... For treatment-naive patients, dolutegravir demonstrated superiority when compared with Department of Health and Human Services treatment guidelines preferred regimens ...

Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in ...

On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...